Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones
08. Januar 2025 16:05 ET
|
Vigil Neuroscience, Inc.
– On track to report data from Phase 1 clinical trial evaluating VG-3927 for the treatment of Alzheimer’s disease in 1Q 2025 – – Final analysis from IGNITE Phase 2 clinical trial evaluating...
Vigil Neuroscience to Present at Upcoming Investor Conferences
12. November 2024 07:00 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update
07. November 2024 07:00 ET
|
Vigil Neuroscience, Inc.
- Final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP planned for first half of 2025 - - Data from Phase 1 clinical trial evaluating VG-3927 in Alzheimer’s Disease...
Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference
05. November 2024 07:00 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927
17. September 2024 07:00 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience to Present at Cantor Global Healthcare Conference
16. September 2024 16:05 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience to Present at Upcoming September Investor Conferences
29. August 2024 07:00 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
13. August 2024 07:00 ET
|
Vigil Neuroscience, Inc.
- Announced $40 million strategic investment from Sanofi; Extended cash runway into 2026 - - Provided update on iluzanebart clinical development strategy to pursue potential accelerated approval...
Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics
01. August 2024 16:05 ET
|
Vigil Neuroscience, Inc.
- CSF1R pathogenic and likely pathogenic variants reported to have an approximate prevalence of 281 per 1 million - - New research supports updated estimates to U.S. prevalence of approximately...
Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)
30. Juli 2024 16:05 ET
|
Vigil Neuroscience, Inc.
- First presentation of clinical data on sTREM2 from SAD cohorts in ongoing Phase 1 clinical trial of VG-3927 in healthy volunteers demonstrate proof-of-pharmacology - - New in vitro and in vivo data...